A.R.T. Advisors’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

A.R.T. Advisors’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-11,900	Closed	-$59K	–	1814
2019 Q2	$59K	Buy	+11,900	New	+$63.2K	﹤0.01%	1238
2018 Q4	–	Sell	-46,668	Closed	-$303K	–	1768
2018 Q3	$303K	Buy	+46,668	New	+$347K	0.01%	1036
2018 Q2	–	Sell	-45,779	Closed	-$1.02M	–	1852
2018 Q1	$1.02M	Buy	+45,779	New	+$1.02M	0.04%	655
2017 Q4	–	Sell	-18,064	Closed	-$281K	–	1755
2017 Q3	$281K	Buy	+18,064	New	+$255K	0.01%	1033

Other funds holding JNCE

TGI

TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

A.R.T. Advisors's JNCE Position: Q3 2019 in Review

A.R.T. Advisors sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q3 2019, closing a stake of 11,900 shares — an estimated $59K sold.

A.R.T. Advisors first reported a position in JNCE in Q3 2017 and held it in 4 quarters. The position peaked at $1.02M in Q1 2018. 77 funds tracked by Wall St. Rank hold JNCE as of Q3 2019.

A.R.T. Advisors reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
A.R.T. Advisors sold 11,900 Jounce Therapeutics, Inc. Common Stock shares in Q3 2019, an estimated $59K.
A.R.T. Advisors first reported a position in Jounce Therapeutics, Inc. Common Stock in Q3 2017 and held it in 4 quarters.
A.R.T. Advisors's Jounce Therapeutics, Inc. Common Stock position peaked at $1.02M in Q1 2018.
77 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q3 2019.

Based on A.R.T. Advisors's 13F filing for Q3 2019, filed 14 Nov 2019.